Eli Lilly and Company (NYSE:LLY) Trading Up 1.4% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) were up 1.4% during mid-day trading on Thursday . The stock traded as high as $1,232.00 and last traded at $1,208.3670. 3,247,617 shares changed hands during mid-day trading, an increase of 0% from the average session volume of 3,238,143 shares. The stock had previously closed at $1,191.74.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Coverage highlighted Eli Lilly as a leader in GLP-1 therapies with an expanding pipeline and diversified growth strategy, reinforcing the bull case despite the stock’s premium valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Shares were lifted by optimism around GLP-1 Medicare inclusion and strong reported results, which investors view as supportive of continued demand and revenue growth. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Another bullish note argued that artificial intelligence could become a long-term growth tailwind for Eli Lilly by improving drug development and operational efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Repeated mentions in pharmaceutical and medical stock roundups suggest Lilly remains one of the sector’s preferred large-cap names for investors seeking growth exposure. Pharmaceutical Stocks To Follow Now – July 2nd
• Positive Sentiment: Additional commentary pointed to Lilly’s appeal to long-term, high-conviction investors, including billionaire hedge fund manager Cliff Asness, adding to the stock’s credibility as a favored healthcare holding. Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
• Neutral Sentiment: One item noted a leadership change at Lilly Korea, which appears operationally routine and unlikely to move the stock on its own. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: General industry pieces about pharmaceutical growth and the sector’s $2 trillion sales trajectory are supportive of sentiment, but they do not add a specific new catalyst for Lilly. Can pharma sustain its $2T trajectory?

Wall Street Analyst Weigh In

Several equities analysts have commented on LLY shares. Bank of America increased their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Berenberg Bank raised their price objective on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company Stock Performance

The firm has a 50 day moving average of $1,065.45 and a two-hundred day moving average of $1,028.14. The stock has a market cap of $1.14 trillion, a P/E ratio of 42.93, a P/E/G ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business posted $3.34 EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently bought and sold shares of LLY. Box Hill Private Wealth LLC increased its stake in Eli Lilly and Company by 3.4% during the second quarter. Box Hill Private Wealth LLC now owns 520 shares of the company’s stock valued at $624,000 after acquiring an additional 17 shares during the period. Versant Capital Management Inc lifted its position in shares of Eli Lilly and Company by 0.5% in the 2nd quarter. Versant Capital Management Inc now owns 3,562 shares of the company’s stock worth $4,272,000 after acquiring an additional 16 shares during the period. CX Institutional lifted its position in shares of Eli Lilly and Company by 5.0% in the 2nd quarter. CX Institutional now owns 35,493 shares of the company’s stock worth $42,572,000 after acquiring an additional 1,675 shares during the period. SWP Investment Management LLC grew its holdings in shares of Eli Lilly and Company by 3.6% during the 2nd quarter. SWP Investment Management LLC now owns 2,857 shares of the company’s stock worth $3,427,000 after purchasing an additional 100 shares in the last quarter. Finally, First County Bank CT grew its holdings in shares of Eli Lilly and Company by 3.9% during the 2nd quarter. First County Bank CT now owns 1,319 shares of the company’s stock worth $1,582,000 after purchasing an additional 49 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.